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Clinical Efﬁcacy of Thrombus Aspiration on 5-Year Clinical Outcomes
in Patients With ST-Segment Elevation Acute Myocardial Infarction
Undergoing Percutaneous Coronary Intervention
Hiroki Watanabe, MD; Hiroki Shiomi, MD; Kenji Nakatsuma, MD; Takeshi Morimoto, MD, PhD; Tomohiko Taniguchi, MD;
Yutaka Furukawa, MD; Yoshihisa Nakagawa, MD; Minoru Horie, MD; Takeshi Kimura, MD; on behalf of the CREDO-Kyoto AMI investigators*
Background-—Adjunctive thrombus aspiration (TA) during primary percutaneous coronary intervention (PCI) was reported to
promote better coronary and myocardial reperfusion. However, long-term mortality beneﬁt of TA remains controversial. The
objective of this study is to investigate the clinical impact of TA on long-term clinical outcomes in patients with ST-segment
elevation myocardial infarction (STEMI) undergoing primary PCI.
Methods and Results-—The CREDO-Kyoto AMI Registry is a large-scale cohort study of acute myocardial infarction patients
undergoing coronary revascularization in 2005–2007 at 26 hospitals in Japan. Among 5429 patients enrolled in the registry, the
current study population consisted of 3536 patients who arrived at the hospital within 12 hours after the symptom onset and
underwent primary PCI. Clinical outcomes were compared between the 2 patient groups with or without TA. During primary PCI
procedures, 2239 out of 3536 (63%) patients underwent TA (TA group). The cumulative 5-year incidence of all-cause death was
signiﬁcantly lower in the TA group than in the non-TA group (18.5% versus 23.9%, log-rank P<0.001). After adjusting for
confounders, however, the risk for all-cause death in the TA group was not signiﬁcantly lower than that in the non-TA group (hazard
ratio: 0.90, 95% CI: 0.76 to 1.06, P=0.21). The adjusted risks for cardiac death, myocardial infarction, stroke, and target-lesion
revascularization were also not signiﬁcantly different between the 2 groups.
Conclusions-—Adjunctive TA during primary PCI was not associated with better 5-year mortality in STEMI patients. ( J Am Heart
Assoc. 2015;4:e001962 doi: 10.1161/JAHA.115.001962)
Key Words: acute coronary syndrome • coronary artery disease • no reﬂow • percutaneous coronary intervention • thrombus
aspiration
A cute myocardial infarction (AMI) can be called thedisease of thrombus: the plaque rupture and the
subsequent thrombus formation results in the occlusion of a
coronary artery. Therefore, primary percutaneous coronary
intervention (PCI) is an established effective therapy for
coronary reperfusion in AMI, and adjunctive thrombus aspi-
ration (TA), which was presumed to improve microvascular
perfusion, was introduced to reduce distal embolism in daily
clinical practice. Several randomized control trials (RCTs)
comparing PCI with or without adjunctive TA have reported
conﬂicting results, and the mortality beneﬁt of TA in ST
segment elevation acute myocardial infarction (STEMI)
patients treated with primary PCI still remains controver-
sial.1–8 The Thrombus Aspiration during Percutaneous Coro-
nary Intervention in Acute Myocardial Infarction Study was
one of the largest trials suggesting 1-year mortality beneﬁt
of TA.9 On the other hand, the Thrombus Aspiration in
ST-Elevation Myocardial Infarction in Scandinavia trial has
reported comparable 1-year mortality between primary PCI
with TA versus PCI only.10 Recently, the Trial of Routine
Aspiration Thrombectomy with PCI versus PCI Alone in
Patients with STEMI (TOTAL) trial has shown no reduction of
the risk of cardiovascular death, recurrent myocardial
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infarction, cardiogenic shock, or New York Heart Association
class IV heart failure within 180 days.11
In an attempt to evaluate whether adjunctive TA has
clinical beneﬁts in the real-world clinical practice, we exam-
ined the impact of adjunctive TA on long-term cardiovascular
outcomes in a large-scale observational database of AMI
patients undergoing primary PCI in Japan.
Methods
Study Population
The Coronary Revascularization Demonstrating Outcome study
in Kyoto (CREDO-Kyoto) AMI registry is a physician-initiated,
non-company-sponsored, multicenter registry enrolling con-
secutive AMI patients undergoing coronary revascularization
within 7 days of symptom onset among 26 centers in Japan
between January 2005 and December 2007 (Appendix). The
relevant review boards or ethics committees in all participating
centers approved the research protocol. Because of retrospec-
tive enrollment, written informed consents from the patients
were waived; however, we excluded those patients who refused
to participate in the study when contacted at follow-up. This
strategy is concordant with the guidelines for epidemiological
studies issued by the Ministry of Health, Labor and Welfare of
Japan.
Among 5429 AMI patients enrolled in this registry, the
current study population consisted of 3536 STEMI patients
who had primary PCI within 12 hours after the onset after
excluding 9 patients with refusal for study participation, 195
patients with coronary artery bypass grafting, 789 non-STEMI
patients, 738 patients with PCI beyond 12 hours after the
symptom onset, and 162 patients whose timing of PCI was
unidentiﬁed (Figure 1).
Deﬁnitions and End Points
The primary outcome measure for the current analysis was all-
cause death. Secondary outcome measures included cardiac
death, noncardiac death, myocardial infarction (MI), stent
thrombosis, stroke, and target-lesion revascularization. Death
was regarded as cardiac in origin unless obvious noncardiac
causes could be identiﬁed. MI was deﬁned according to the
Arterial Revascularization Therapy Study.12 Stent thrombosis
was deﬁned according to the Academic Research Consortium
deﬁnition.13 Target-lesion revascularization was deﬁned as
either repeated percutaneous or surgical revascularization for
a lesion anywhere within the stent or the 5-mm borders
proximal or distal to the stent. The detailed deﬁnitions of
baseline clinical characteristics were described previously.14
Data Collection for Baseline Characteristics and
Follow-up Events
Demographic, angiographic, and procedural data were col-
lected from hospital charts or hospital databases according to
CREDO-Kyoto AMI registry 
5429 patients with AMI
4436 with STEMI treated by PCI
789 with NSTEMI
195 underwent CABG
738 underwent PCI 
beyond 12 hours
9 refused study particitation
2239 underwent conventional PCI plus thrombus 
aspiration(TA group)
1297 underwent only conventional PCI
(non-TA group)
3536 with STEMI treated by PCI 
within 12 hours after the onset
162 unknown onset
Figure 1. Study ﬂow chart. AMI indicates acute myocardial infarction; CABG, coronary artery bypass
grafting; CREDO-Kyoto AMI Registry, Coronary Revascularization Demonstrating Outcome Study in Kyoto
Acute Myocardial Infarction Registry; NSTEMI, non-ST-segment elevation myocardial infarction; PCI,
percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; TA, thrombus
aspiration.
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the prespeciﬁed deﬁnitions by experienced clinical research
coordinators from the study management center (Research
Institute for Production Development, Kyoto, Japan) (Appen-
dix). In this retrospective cohort study, data collection for
follow-up events was performed in 2010 and 2012. Collection
of follow-up information was mainly conducted through review
of inpatient and outpatient hospital charts by the clinical
research coordinators, and additional follow-up information
was collected through contact with patients, relatives, and/or
referring physicians by sending mail with questions regarding
vital status, subsequent hospitalizations, and status of
antiplatelet therapy. Death, MI, stent thrombosis, and stroke
were adjudicated by the clinical event committee (Appendix).
Median follow-up duration was 1843 (interquartile range:
1496 to 2157) days. Complete 1-, 3-, and 5-year follow-up
information was obtained in 98%, 95%, and 64% of patients.
Statistical Analysis
Categorical variables were presented as numbers and per-
centages and compared using the v2 test or Fisher exact test.
Continuous variables were presented as the mean and SD or
the median and interquartile range. Continuous variables were
compared using the Student t test or the Wilcoxon rank sum
test based on their distributions. Cumulative incidences were
estimated by the Kaplan–Meier method and differences were
evaluated with the log-rank test. The effect of the TA group as
compared with the non-TA group was expressed as hazard ratio
(HR) and their 95% CI. Multivariable Cox proportional hazard
models were employed to assess the HR of the TA group as
compared with the non-TA group, adjusting for 41 clinically
relevant factors listed in Table 1. In addition, we computed the
adjusted event curves of the 2 groups using the methods
described by Ghali et al15 Consistent with our previous reports,
continuous variables were dichotomized by clinically meaning-
ful reference values or median values.14 We also evaluated the
effect of TA on the primary outcome measure in several
clinically relevant subgroups stratiﬁed by age (≥75 years or
<75 years), gender (male or female), diabetes mellitus (with or
without diabetes mellitus), total ischemic time (0 to 2, 2 to 6, 6
to 12 hours), culprit lesion (left anterior descending culprit or
non–left anterior descending culprit), initial Thrombolysis In
Myocardial Infarction (TIMI) ﬂow grade (Thrombolysis In
Myocardial Infarction ﬂow grade 0 or Thrombolysis In Myocar-
dial Infarction ﬂow grade ≥1), and hemodynamic status (Killip 1
to 3 or Killip 4). Multivariable Cox proportional hazard models
were similarly developed for the subgroup analysis. In addition
to the adjunctive TA use, 24 variables with P<0.05 in the
previously described full model were included in the multivar-
iable models for the subgroup analysis, reﬂecting our prefer-
ence for parsimonious models to avoid overﬁtting. All
statistical analyses were conducted using JMP version 10.0.2
(SAS Institute Inc, Cary, NC) or SAS version 9.3 (SAS Institute
Inc). All the statistical analyses were 2-tailed and P values
<0.05 were considered statistically signiﬁcant.
Results
Among 3536 STEMI patients with primary PCI in the current
study, 2239 patients (63%) received adjunctive TA during
primary PCI (TA group). Baseline characteristics differed
signiﬁcantly in several aspects between the TA and the non-
TA group (Table 1).
The cumulative 5-year incidence of all-cause death was
signiﬁcantly lower in the TA group than in the non-TA group
(18.5% versus 23.9%, log-rank P<0.001) (Table 2 and Fig-
ure 2). However, after adjusting for confounders, the adjusted
risk of the TA group relative to the non-TA group for all-cause
death was not signiﬁcantly different (HR: 0.90, 95% CI: 0.76 to
1.06, P=0.21) (Table 2). Similarly, the adjusted risks for
cardiac death, noncardiac death, and target-lesion revascu-
larization were not signiﬁcantly different between the 2
groups (HR: 0.99, 95% CI: 0.79 to 1.24, P=0.91; HR: 0.78,
95% CI: 0.62 to 1.03, P=0.08; and HR: 0.90, 95% CI: 0.76 to
1.07, P=0.23, respectively), although the cumulative 5-year
incidences of cardiac death, noncardiac death, and target-
lesion revascularization were signiﬁcantly lower in the TA
group (11.1% versus 14.5%, log-rank P=0.01, 8.3% versus
11.0%, log-rank P<0.001, and 21.6% versus 25.8%, log-rank
P=0.007, respectively) (Table 2). The cumulative 5-year
incidences of and the adjusted risks for MI, stroke, and stent
thrombosis were not signiﬁcantly different between the TA
and non-TA group (Table 2).
The comparable adjusted risk for all-cause death between
the TA and non-TA groups was consistently observed across
subgroups stratiﬁed by gender, diabetes mellitus, and location
of culprit lesion (Figure 3). In the subgroups of patients
<75 years of age, total ischemic time 0 to 2 hours, initial
thrombolysis in myocardial infarction ﬂow grade 1 to 3, and
Killip class 4, the adjusted risk for all-cause death in the TA
group was signiﬁcantly lower than that in the non-TA group.
However, there was not a signiﬁcant interaction between
those 4 subgroup factors and the effect of TA on the risk for
all-cause death (Figure 3).
Discussion
The main ﬁnding of the current analysis is that mortality
beneﬁt of adjunctive TA during primary PCI was not observed
in STEMI patients with primary PCI in real-world clinical
practice. Several RCTs reported the beneﬁts of adjunctive use
of TA during primary PCI.4,7,9 The Thrombus Aspiration during
Percutaneous Coronary Intervention in Acute Myocardial
DOI: 10.1161/JAHA.115.001962 Journal of the American Heart Association 3




























Age 66.612 68.912.1 <0.001
>75 years*† 640 (28.6%) 451 (34.8%) <0.001
Male gender* 1700 (75.9%) 933 (71.9%) 0.009
Body mass index 23.83.5 23.33.4 <0.001
<25.0 kg/m2*† 1557 (69.5%) 977 (75.3%) <0.001
Hypertension*† 1749 (78.1%) 1011 (77.9%) 0.91
Diabetes mellitus 659 (29.4%) 459 (35.4%) <0.001
On insulin therapy*† 83 (3.7%) 72 (5.6%) 0.01
Current smoking* 953 (42.6%) 492 (37.9%) 0.007
Previous heart failure*† 686 (30.6%) 422 (32.5%) 0.24
Multivessel disease*† 1054 (47.1%) 738 (56.9%) <0.001
Mitral regurgitation 3-4/4*† 55 (2.5%) 43 (3.3%) 0.14
Previous myocardial infarction* 196 (8.8%) 129 (9.9%) 0.24
Previous stroke*† 175 (7.8%) 136 (10.5%) 0.008
Peripheral vascular disease* 65 (2.9%) 42 (3.2%) 0.58
Previous PCI or CABG 215 (9.6%) 121 (9.3%) 0.79
eGFR <30, without hemodialysis*† 79 (3.5%) 62 (4.8%) 0.07
Hemodialysis*† 19 (0.9%) 29 (2.2%) <0.001
Atrial fibrillation*† 224 (10.0%) 114 (8.8%) 0.23
Anemia (hemoglobin <11.0 g/dL)* 185 (8.3%) 136 (10.5%) 0.03
Thrombocytopenia (platelet <1009109/L)*† 42 (1.9%) 28 (2.2%) 0.56
COPD* 69 (3.1%) 41 (3.2%) 0.90
Liver cirrhosis*† 52 (2.3%) 32 (2.5%) 0.79
Malignancy*† 173 (7.7%) 118 (9.1%) 0.16
Presentation
Killip class ≤2 1873 (83.7%) 1053 (81.2%) 0.06
Killip class 4*† 324 (14.5%) 206 (15.9%) 0.26
Initial TIMI flow grade=0* 1620 (72.4%) 664 (51.2%) <0.001
Total ischemic time (median hours) 2.0 (1.0 to 3.9) 2.3 (1.1 to 4.4) 0.004
IABP use 369 (16.5%) 218 (16.8%) 0.80
PCPS use 62 (2.8%) 39 (3.0%) 0.68
Lesion and procedural characteristics
Infarcted area <0.001
Anterior wall 961 (42.9%) 701 (54.0%)
Inferior wall 1066 (47.6%) 397 (30.6%)
Lateral wall 36 (1.6%) 73 (5.6%)
Unprotected LMCA 79 (3.5%) 84 (6.5%) <0.001
Chronic total occlusion 207 (9.3%) 171 (13.2%) <0.001
Target lesion
Unprotected LMCA*† 62 (2.8%) 60 (4.6%) 0.004
Continued
DOI: 10.1161/JAHA.115.001962 Journal of the American Heart Association 4





















Infarction Study trial demonstrated signiﬁcantly lower 1-year
mortality by TA use. Reﬂecting these results, the current
STEMI guidelines recommend the use of adjunctive TA during
primary PCI as class IIa indication with a level of evidence B.16
Most of these trials, however, did not have adequate power to
detect mortality beneﬁt of TA and evaluated surrogate end
points such as myocardial blush grade or resolution of ST-
segment elevation instead of mortality.4–8 Indeed, the recent
3 RCTs reported the absence of clinical beneﬁt of TA in STEMI
patients with primary PCI.2,3,11 First, the INFUSE-AMI trial,
comparing primary PCI plus adjunctive TA with primary PCI







Proximal LAD* 1146 (51.2%) 767 (59.1%) <0.001
LAD 1184 (52.9%) 825 (63.6%) <0.001
LCX 394 (17.6%) 278 (21.4%) <0.001
RCA 1188 (53.1%) 522 (40.2%) <0.001
Bifurcated lesion*† 533 (23.8%) 383 (29.5%) <0.001
Chronic total occlusion* 61 (2.7%) 50 (3.9%) 0.07
Side-branch stenting* 58 (2.6%) 52 (4.0%) 0.02
Implanted stents
MeanSD 1.61.0 1.81.2 <0.001
Median (IQR) 1 (1 to 2) 1 (1 to 2)
Total stent length
MeanSD 34.023.1 36.827.7 0.48
Median (IQR) 24 (18 to 42) 27 (18 to 44)
>28 mm* 839 (40.4%) 517 (44.6%) 0.02
Minimal stent diameter
MeanSD 3.10.5 2.90.4 <0.001
Median (IQR) 3.0 (3.0 to 3.5) 3.0 (2.5 to 3.0)
<3.0 mm* 513 (24.7%) 476 (41.1%) <0.001
Distal protection 249 (11.1%) 26 (2.0%) <0.001
Medication at discharge
Aspirin 2210 (98.7%) 1272 (98.1%) 0.15
Thienopyridine 2157 (96.3%) 1204 (92.8%) <0.001
Cilostazole* 823 (36.8%) 448 (34.5%) 0.19
Statin*† 1220 (54.5%) 671 (51.7%) 0.11
ACE-I/ARB*† 1654 (73.9%) 898 (69.2%) 0.003
b-Blocker*† 946 (42.3%) 517 (39.9%) 0.16
Calcium channel blocker* 397 (17.7%) 307 (23.7%) <0.001
Nitrate*† 622 (27.8%) 402 (31.0%) 0.04
Nicorandil*† 595 (26.6%) 406 (31.3%) 0.003
Warfarin* 264 (11.8%) 123 (9.5%) 0.03
PPI* 786 (35.1%) 406 (31.3%) 0.02
H2 blocker* 760 (33.9%) 429 (33.1%) 0.60
Categorical variables are expressed as number (%) unless otherwise indicated. Continuous variables are shown as meanSD or median (interquartile range). ACE-I/ARB indicates
angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular
ﬁltration rate; IABP, intra-aortic balloon pumping; IQR, interquartile range; LAD, left anterior descending; LCX, left circumﬂex; LMCA, left main coronary artery; PCI, percutaneous coronary
intervention; PCPS, percutaneous cardiopulmonary support; PPI, proton-pump inhibitor; RCA, right coronary artery; TA, thrombus aspiration; TIMI, thrombolysis in myocardial infarction.
*Potential independent variables selected for multivariable analysis.
†Potential independent variables selected for multivariable analysis in the speciﬁc subgroups.
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terms of infarct size at 30 days assessed by cardiac magnetic
resonance imaging.3 Second, the Thrombus Aspiration in ST-
Elevation Myocardial Infarction in Scandinavia trial is a
multicenter, randomized-controlled clinical trial assessing
the mortality beneﬁt of TA with adequate power (enrolling
7244 patients) and characterized by using the national
comprehensive registry. The Thrombus Aspiration in ST-
Elevation Myocardial Infarction in Scandinavia trial failed to
show that routine TA could reduce 1-year mortality of STEMI
patients treated with primary PCI.10 Finally, in the TOTAL trial,
which has been the most recently presented, routine TA plus
primary PCI, as compared with conventional PCI alone, did not
reduce the risk of cardiovascular death, recurrent MI,
cardiogenic shock, or class IV heart failure within 180 days.
The ﬁnding of the TOTAL trial concerning the mortality beneﬁt
of thrombectomy is consistent with that of the Thrombus
Aspiration in ST-Elevation Myocardial Infarction in Scandinavia
trial.11 Moreover, another important ﬁnding in the TOTAL trial
is that routine TA was associated with a signiﬁcantly higher
rate of stroke. In this respect, previous studies including trials
of rheolytic thrombectomy reported a similar ﬁnding.17,18
Certainly the mechanism of stroke might be embolization of
thrombus or air during the procedure, but the explanation
sounded unreasonable because the period of a continued
Table 2. Crude and Adjusted 5-Year Clinical Outcomes TA Group Versus Non-TA Group
TA Group Non-TA Group







All-cause death 393 (18.5%) 297 (23.9%) 0.74 (0.67 to 0.86) <0.001 0.90 (0.76 to 1.06) 0.21
Cardiac death 239 (11.1%) 180 (14.5%) 0.78 (0.65 to 0.95) 0.01 0.99 (0.79 to 1.24) 0.91
Noncardiac death 154 (8.3%) 117 (11.0%) 0.68 (0.54 to 0.85) <0.001 0.78 (0.62 to 1.03) 0.08
Myocardial infarction 115 (5.9%) 78 (7.1%) 0.83 (0.63 to 1.09) 0.18 0.88 (0.65 to 1.20) 0.42
Stent thrombosis 55 (2.6%) 33 (2.9%) 0.91 (0.60 to 1.40) 0.68 0.92 (0.59 to 1.45) 0.71
Stroke 108 (5.5%) 77 (7.0%) 0.74 (0.56 to 0.98) 0.03 0.79 (0.58 to 1.10) 0.16
TLR 436 (21.6%) 294 (25.8%) 0.82 (0.71 to 0.95) 0.01 0.90 (0.76 to 1.07) 0.23
Cumulative incidence was estimated by the Kaplan–Meier method. HR indicates hazard ratio; TA, thrombus aspiration; TLR, target-lesion revascularization.
Figure 2. Crude and adjusted Kaplan–Meier curves for cumulative incidence of all-cause death. TA
indicates thrombus aspiration.
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increase in the rate of stroke was between 30 and 180 days,
but not within 24 hours after the procedure. As the possibility
of a chance ﬁnding as the explanation cannot be eliminated
because of the relatively small number of events, further
studies should be warranted to clarify the safety of TA for
stroke risk. In spite of the TOTAL trial, there is no denying that
the procedure of TA has the potential to make intervention
easier in selected cases without any complex manipula-
tion.1,4–6,19 However, judging from the results of major trials
including the safety concern about potential stroke risk,
prudent attitudes should be taken toward the procedure in
daily clinical practice.3,10,11,17–19
Several previous observational studies in real-world clin-
ical practice reported the mortality beneﬁt of TA.20–23
Consistent with the ﬁndings of the 3 RCTs, however, long-
term mortality beneﬁt of TA during primary PCI could not be
observed in the current study, reﬂecting real-world clinical
practice. The possibility cannot be ruled out that TA might be
beneﬁcial in high-risk patients excluded from the trials, but
in our analysis, the beneﬁt of TA could not be observed in
any subsets of patients, including high-risk patients such as
elderly people or cardiogenic-shock cases. As in the INFUSE-
AMI trial, the efﬁcacy of TA was evaluated according to the
total ischemic time as subgroup analysis in our study. In the
patients with total ischemic time 0 to 2 hours, the adjusted
risk for all-cause death in the TA group was signiﬁcantly
lower than that in the non-TA group, but there was not a
signiﬁcant interaction between the total ischemic time and
the effect of TA. Therefore, a mortality beneﬁt of adjunctive
TA cannot be expected in most STEMI patients undergoing
primary PCI in the current clinical practice, where the
management of STEMI patients has achieved great improve-
ment with respect to both reperfusion therapy and adjunc-
tive medical therapy.
Clinical Implications
The 3 latest RCTs demonstrated no clinical beneﬁt of routine
TA, the results of which are consistent with those of the current
analysis. From these clinical trials, the recommendation of
routine TA in the current guideline should be reconsidered.
However, the clinical efﬁcacy of TA cannot be totally denied,
and further investigation evaluating the clinical beneﬁt of
selective TA should be performed. In some selective cases, TA
could facilitate the primary PCI procedure by more clearly
delineating the true lesion length for appropriate stenting. In
addition, one of themost important ﬁndings in the TOTAL trial is
an increased rate of stroke. The safety concern about stroke
associated with TA should also be investigated in future studies.
Limitations
Our study has several limitations. First, this is not a RCT but
an observational study. The indication of TA was at the
0.00 0.50 1.00 1.50 2.00
Variables
TA group Non-TA group Adjusted Interaction No. of events /No. of patients No. of events /No. of patients Hazard Ratio
(Cumulative Incidence) (Cumulative Incidence) (95?CI) p value p value
N=2239 N=1297
Age
>=75 years old 250/640(39%) 193/451(43%) 0.95(0.78-1.16) 0.60 0.11 
?75 years old 176/1599(11%) 131/846(16%) 0.77(0.61-0.98) 0.03 
Male 280/1700(17%) 216/933(23%) 0.86(0.72-1.03) 0.10 0.08 
Female 146/539(27%) 108/364(30%) 0.99(0.76-1.28) 0.92 
Diabetes 139/659(21%) 127/459(28%) 0.95(0.74-1.22) 0.69 0.90 
Non-diabetes 287/1580(18%) 197/838(24%) 0.87(0.72-1.05) 0.14 
Total ischemic time
<=2hours 178/1132(17%) 139/601(24%) 0.78(0.63-0.98) 0.03 0.24 
2-6 hours 158/821(20%) 110/501(23%) 1.05(0.83-1.34) 0.67 
6-12hours 57/286(21%) 48/195(26%) 1.04(0.69-1.56) 0.87 
Culprit lesion
LAD culprit 200/958(21%) 185/694(27%) 1.05(0.85-1.30) 0.64 0.99 
Non-LAD culprit 226/1281(18%) 139/603(23%) 0.85(0.69-1.06) 0.16
Initial TIMI grade 0 340/1620(21%) 179/664(27%) 0.91(0.75-1.09) 0.30 0.13 
Initial TIMI grade 1-3 86/619(14%) 145/633(23%) 0.72(0.55-0.95) 0.02
Killip class4(cardiogenic shock) 142/324(44%) 111/206(54%) 0.77(0.59-0.99) 0.045 0.55
Killip class1-3 284/1915(15%) 213/1091(20%) 0.94(079-1.13) 0.53
PCI?TA better          PCI alone better
Figure 3. Subgroup analyses and forest plots of hazard ratio for all-cause death. LAD indicates left anterior descending; PCI,
percutaneous coronary intervention; TA, thrombus aspiration; TIMI, thrombolysis in myocardial infarction.
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discretion of the operator or of the hospital, so that outcomes
might be affected by the effect of the operator’s skill or of the
hospital’s practice level. In addition, baseline patient charac-
teristics differed signiﬁcantly between the TA and non-TA
groups. Despite the appropriate statistical adjustment for
potential confounders, unmeasured confounding factors
might have inﬂuenced the results of the current study.
Second, the current study did not evaluate detailed angio-
graphic ﬁndings such as thrombus burden or myocardial blush
grade. Third, as glycoprotein IIa/IIIb inhibitors are not
currently available in Japan, much caution is required in
generalizing these results to patients outside Japan.
Conclusions
Adjunctive TA during primary PCI was not associated with
better 5-year mortality in STEMI patients with primary PCI.
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